Home > Healthcare > Pharmaceuticals > Finished Drug Form > abortion drugs market
Get a free sample of Abortion Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Abortion Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
These leading players are actively engaging in the production and distribution of abortion drugs and competing to meet the growing demand to widen their customer base and global presence. They are continuing to innovate and expand their offerings by adapting to evolving healthcare needs and regulatory changes. Partnership strategies and R&D initiatives are also employed by these firms to proliferate their portfolio.
Major players in the abortion drugs industry include:
The mifepristone segment of the market is poised to record 8.6% CAGR from 2024-2032, propelled by the rising pivotal role of mifepristone in abortion procedures.
Global abortion drugs market size was valued at over USD 24.42 billion in 2023 and is estimated to grow at 8.2% CAGR from 2024-2032, driven by the rising rate of abortions.
Cipla Limited, Endo International plc, Exelgyn, Gedeon Richter plc, Jubilant Life Sciences, Lupin Limited, and Mylan N.V. among others.
North America abortion drugs market size recorded decent growth in 2023 and is predicted to witness 8.4% CAGR through 2032, owing to the presence of an improved healthcare infrastructure.